Interstitial Lung Disease News and Research

RSS

Interstitial lung disease (ILD) is a broad group of lung diseases comprising of more than a hundred distinct disorders. All of these involve scarring or inflammation of the interstitial lung tissue and affect the volume of oxygen that can reach the bloodstream via the respiratory system.

LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation

The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. The study results are posted to the medRxiv* preprint server.

6 Jan 2022

Correlation between idiopathic pulmonary fibrosis and COVID-19

A new study investigates the genetic overlap between COVID-19 and idiopathic pulmonary fibrosis to identify possible shared biological mechanisms.

14 Dec 2021

Black patients with systemic sclerosis may experience poorer outcomes more often than others

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups, and these worrying disparities may be driven by several socioeconomic factors.

2 Nov 2021

Teen’s mysterious condition spurs the opening of Childhood Interstitial Lung Disease Clinic

Thirteen-year-old Gregory Rhoden's condition has been a mystery his entire life. He was born prematurely and his lungs seemed underdeveloped.

7 Oct 2021

New study aims to find early drivers of pulmonary fibrosis in at-risk patient population

Researchers at Vanderbilt University Medical Center are leading a study designed to identify early drivers of pulmonary fibrosis in an at-risk patient population. Funding for the research, which could help predict early disease at the cellular level and possibly drive the development of novel therapies, is being provided by Three Lakes Foundation.

6 Oct 2021

New model shows how dysfunction in the air sacs initiates fibrotic cascade

Idiopathic pulmonary fibrosis (IPF) is the most common and severe form of lung disease characterized by relentless scarring leading to death within an average of four years from the time of diagnosis.

31 Aug 2021

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.

9 Aug 2021

Researchers discover potential biomarker for lung disease in scleroderma patients

Researchers have discovered a protein that may predict disease severity for a lung condition that often proves fatal to patients with scleroderma.

3 Aug 2021

Baseline use of DMARDs linked with COVID-19 severity in rheumatoid arthritis patients

Due to sample size limitations, previous studies of DMARD use and COVID-19 outcomes have combined several different rheumatic diseases and medications, and investigated a single outcome- for example, the risk of hospitalization.

18 Jun 2021

Are women more likely to develop long COVID?

Researchers found different groups of symptoms persisting after coronavirus disease 2019 (COVID-19), with fatigue and higher IL-6 levels common in women. About 75% of the patients they treated were women, indicating a link between sex hormones and immune response.

8 Jun 2021

Long COVID patients at higher risk of small airway disease

The preprint discussed herein describes the effects of SARS-CoV-2 on lung structure and function in patients with long COVID.

2 Jun 2021

FDA approves targeted therapy for tumors with KRAS mutations

Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

29 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

CHEST releases new clinical guidelines to improve diagnosis of hypersensitivity pneumonitis

The American College of Chest Physicians recently released new clinical guidelines on the Diagnosis and Evaluation of Hypersensitivity Pneumonitis (HP).

10 May 2021

Repurposing an anti-inflammatory drug can prevent lung disease in patients with systemic sclerosis

Research led by Michigan Medicine's Scleroderma Program and published in Arthritis & Rheumatology found that tocilizumab, a FDA-approved anti-inflammatory drug used to combat rheumatoid arthritis, can prevent lung disease in patients with systemic sclerosis if detected early enough in the disease course.

31 Mar 2021

FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression

Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.

13 Feb 2021

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.

18 Dec 2020

CN Bio and University of Melbourne announce partnership focused on respiratory therapies for recovering COVID-19 patients

CN Bio, a leading cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.

18 Dec 2020

CN Bio and the University of Melbourne collaborate to advance therapies for respiratory complications in recovered COVID-19 patients

From AXT Pty Ltd 16 Dec 2020

New collaborative study to address key questions about COVID-19

A new nationwide study of more than 50,000 individuals is underway to determine factors that predict disease severity and long-term health impacts of COVID-19.

11 Dec 2020